Strategic Licensing Agreement with Kelix Bio Expands Oncology Pipeline
HIBA Pharma and Kelix Bio formalize a landmark licensing agreement that significantly expands our oncology pipeline with next-generation targeted therapies.
In a landmark move for regional healthcare, HIBA Pharma and Kelix Bio have formalized a strategic licensing agreement. This partnership significantly expands our oncology pipeline, bringing next-generation targeted therapies to patients in the UAE and the broader GCC region.
The agreement encompasses the technology transfer and local manufacturing of several critical oncology molecules. By combining Kelix Bio's innovative formulations with HIBA Pharma's state-of-the-art cGMP manufacturing capabilities in KEZAD, we are taking a major step towards ensuring self-sufficiency in life-saving cancer treatments.